🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 55 of 757 · Phase 3 first, then by program name

  1. FLUOROURACIL, CAPECITABINE, Zimberelimab, OXALIPLATIN, FLUOROURACIL, CALCIUM FOLINATE, DOMVANALIMAB, NIVOLUMAB, FLUOROURACIL, CAPECITABINE

    Arcus Biosciences

    Metastatic Esophageal or Gastric Cancer, Esophageal or Gastric Cancer

    phase 3 small molecule active

    1 trial

  2. FLUOROURACIL, CISPLATIN, CAPECITABINE, CISPLATIN, TRASTUZUMAB, Placebo for Pembrolizumab, OXALIPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE, TRASTUZUMAB

    Merck Sharp and Dohme

    Gastric or gastroesophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  3. FLUOROURACIL, DOCETAXEL, OPDIVO 10 mg/mL concentrate for solution for infusion., OXALIPLATIN, CALCIUM LEVOFOLINATE, CISPLATIN, DOXORUBICIN HYDROCHLORIDE

    Verona Pharma Ireland Limited

    Gastric adenocarcinoma with peritoneal metastases

    phase 3 small molecule active

    1 trial

  4. FLUOROURACIL, Tecentriq 1 200 mg concentrate for solution for infusion, CALCIUM FOLINATE PENTAHYDRATE, OXALIPLATIN

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    stage III colon adenocarcinoma with deficient MMR

    phase 3 small molecule active

    1 trial

  5. FLUTICASONE , Dupilumab, SALBUTAMOL , BUDESONIDE , MONTELUKAST , Matched placebo for test (dupilumab low dose), Matched placebo for test (dupilumab high dose), BECLOMETASONE , Dupilumab, SALMETEROL AND FLUTICASONE

    Sanofi Pharma Bristol-Myers Squibb

    Respiratory tract diseases - Wheezing, Asthma

    phase 3 small molecule active

    1 trial

  6. FMX-101, 4% minocycline foam

    VYNE Therapeutics

    Acne Vulgaris

    phase 3 small molecule completed

    2 trials

  7. FMX101

    VYNE Therapeutics

    Acne Vulgaris

    phase 3 small molecule completed

    1 trial

  8. FMX103 1.5%

    VYNE Therapeutics

    Papulopustular Rosacea

    phase 3 small molecule completed

    1 trial

  9. FMX103 minocycline foam 1.5%

    VYNE Therapeutics

    Facial Papulopustular Rosacea

    phase 3 small molecule completed

    2 trials

  10. FOSFOMYCIN , SULFAMETHOXAZOLE AND TRIMETHOPRIM

    Tour Hekla

    Benign Prostate Hyperplasia

    phase 3 small molecule active

    1 trial

  11. FS MDPI

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule completed

    2 trials

  12. FST-201 (dexamethasone 0.1%) Otic Suspension

    Takeda Pharmaceuticals International AG

    Acute Fungal Otitis Externa

    phase 3 small molecule terminated

    1 trial

  13. FST-201 (dexamethasone 0.1%) Otic Suspension

    Takeda Pharmaceuticals International AG

    Acute Otitis Externa

    phase 3 small molecule terminated

    1 trial

  14. FST201 (dexamethasone 0.1% with povidone-iodine 1%)

    Takeda Pharmaceuticals International AG

    Acute Otitis Externa

    phase 3 small molecule completed

    1 trial

  15. FULVESTRANT , EXEMESTANE , ABEMACICLIB

    Eli Lilly Co.

    Breast Cancer

    phase 3 small molecule active

    1 trial

  16. FUROSEMIDE , DULOXETINE

    Cancer Prevention Pharma (Ireland) Limited

    ER positive HER2 negative breast cancer stages I-II

    phase 3 small molecule active

    1 trial

  17. FUROSEMIDE, FUROSEMIDE, FUROSEMIDE, HYDROCHLOROTHIAZIDE

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Acute Heart Failure

    phase 3 small molecule active

    1 trial

  18. FX006

    Pacira Ireland Limited

    Osteoarthritis, Hip

    phase 3 small molecule terminated

    1 trial

  19. FX006

    Pacira Ireland Limited

    Osteoarthritis of the Knee

    phase 3 small molecule completed

    2 trials

  20. FX006 32 mg

    Pacira Ireland Limited

    Osteoarthritis, Knee

    phase 3 small molecule completed

    1 trial

  21. FX006 32 mg

    Pacira Ireland Limited

    Osteoarthritis of the Knee

    phase 3 small molecule completed

    4 trials

  22. Fabrazyme 35 mg powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671, Replagal 1 mg/ml concentrate for solution for infusion., Replagal 1 mg/ml concentrate for solution for infusion., Galafold 123 mg hard capsules, Replagal 1 mg/ml concentrate for solution for infusion.

    Sanofi Pharma Bristol-Myers Squibb

    Fabry’s disease

    phase 3 small molecule active

    1 trial

  23. Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)

    Takeda Pharmaceuticals International AG

    Hemophilia A or B With Inhibitors

    phase 3 mab completed

    1 trial

  24. Farletuzumab

    United Therapeutics Europe Ltd

    Ovarian Cancer

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources